4/24/2014 7:11:30 AM
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results and a development pipeline update for the three months ended March 31, 2014. The Company reported net product sales of Soliris® (eculizumab) of $566.6 million, including reimbursement of prior year shipments related to an agreement with the French government of $87.8 million, an increase of 67 percent from the same period in 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by